The newly developed KRAS G12C inhibitors such as sotorasib and adagrasib, which bind irreversibly to the unique cysteine residue within KRAS G12C, demonstrate promising efficacy against pancreatic cancer, non-small-cell lung cancer, and colorectal cancer.25, 26, 27, 28 An expanded phase II cohort of the KRYSTAL-1 study, designed to evaluate adagrasib in various solid tumors carrying KRAS G12C-mutations, treated 12 patients with advanced BTC. This evidence concerns the gene KRAS and non-small cell lung carcinoma.